Technology
Health
Biotechnology

Adverum Biotechnologies

$9.21
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.05 (0.55%) Today
-$0.01 (-0.11%) After Hours

Why Robinhood?

You can buy or sell ADVM and other stocks, options, ETFs, and crypto commission-free!

About

Adverum Biotechnologies, Inc. Common Stock, also called Adverum Biotechnologies, is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. Read More It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr. and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.

Employees
82
Headquarters
Menlo Park, California
Founded
2006
Market Cap
583.95M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
569.17K
High Today
$9.30
Low Today
$9.05
Open Price
$9.06
Volume
195.83K
52 Week High
$9.45
52 Week Low
$2.62

Collections

Technology
Health
Biotechnology
Medical
Gene Therapies
2016 IPO
US
North America

News

Seeking AlphaMay 24

Adverum Biotechnologies: A High Risk/High Reward Biotech Play In 2019

The recent lift of clinical hold on investigational ADVM-022 therapy by the FDA has reignited interest in Adverum Biotechnologies.

135
Seeking AlphaMay 20

Updated Investment Thesis On Adverum Biotechnologies

We take a look at that and other recent events as well as the first new analyst activity on the stock so far in 2019. The stock of Adverum Biotechnologies rose some 40% in trading this week, thanks to a lifting of an FDA hold on its primary drug candidate. Words rich in meaning can be cheap in sound effects." - Dejan Stojanovic Today, we revisit a 'Busted IPO' that has been 'en fuego' so far in 2019. The stock added some 40% to its recent gains this week even as the overall market sank. We will discuss r...

452
NasdaqMay 8

Adverum Biotechnologies Reports First Quarter 2019 Financial Results and Provides Corporate Update

MENLO PARK, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today reported financial results for the first quarter ended March 31, 2019 and provided a corporate update. "Our primary focus is on advancing ADVM-022, our novel gene therapy designed as a single-administration treatment for wet AMD," said Leone Patterson, chief executive officer of Adverum Biotechnologies....

797

Earnings

-$0.34
-$0.30
-$0.27
-$0.23
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.